Chiusura precedente | 3,5400 |
Aperto | 3,5700 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 3,5700 - 3,6100 |
Intervallo di 52 settimane | 3,5700 - 3,6100 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 789.878 |
Beta (5 anni mensile) | 1,89 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,3550 |
Prossima data utili | N/D |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisable
Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and AsiaNANORAY-312 now has sites activated across 80 sites globallyPhase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected in 2H 2024 PARIS and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expa
PARIS and CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it has ended the liquidity contract signed on October 23, 2012 with Gilbert Dupont. The termination is effective from December 20th, 2022, after the close of Euronext market. On the termination date of this contrac